Company ProfilePremium

Deepak Nitrite Limited

Company Profile Analysis

Tickers: DEEPAKNTR.NS, 506401.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Deepak Nitrite Limited - Company showcase

Year Founded & Workforce

1970

5,000 Employees

Deepak Nitrite Limited logo

Deepak Nitrite Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Deepak Nitrite Limited Overview

Deepak Nitrite is one of India's largest chemical-intermediates groups, headquartered in Vadodara and controlled by the Mehta family. It operates through two reporting segments: Advanced Intermediates (AI), a legacy portfolio of nitrites, nitro-aromatics, xylidines, cumidines, oximes, fuel additives and optical brighteners sold to agrochemical, dyes/pigments, pharma, rubber and paper customers in India and 50+ export markets; and Phenolics, run through wholly owned subsidiary Deepak Phenolics, which makes phenol, acetone and isopropyl alcohol (IPA) at Dahej and holds roughly half of the Indian phenol/acetone market. Phenolics now generates about two-thirds of revenue and the large majority of segment profit. The group is in the middle of its largest-ever investment cycle — an approximately INR 11,500 Cr propylene-to-polycarbonate chain via Deepak Chem Tech, plus a newly approved INR 2,500 Cr bisphenol-A plant — repositioning it from an intermediates maker toward an integrated import-substitution platform in phenol derivatives and engineering polymers.


What the company does

Deepak Nitrite manufactures and sells chemical intermediates — molecules that customers transform into finished products such as crop-protection active ingredients, dyes and pigments, rubber chemicals, pharmaceuticals, paper brighteners, solvents, resins and plastics. The company does not sell to consumers; it is a business-to-business supplier positioned upstream and midstream in the chemical value chain.

Company's own description (paraphrased from the FY2026 results presentation): DNL characterizes itself as one of India's fastest-growing and most trusted chemical-intermediates companies, with a diversified product portfolio serving multiple industries and applications. It emphasizes recognition by global customers as a responsible manufacturer and preferred supplier, highlights its process expertise and operational excellence, and states that it has 7 modern manufacturing facilities, exports to 50+ countries across 6 continents, and is India's largest producer of phenol, acetone, IPA and sodium nitrite. The presentation cites 36+ products, 56+ applications, FY2026 total revenue of INR 7,947 Cr and a workforce of 6,100+.

Independent characterization: In economic substance, DNL is two businesses under one roof:

  1. A cumene-based phenol/acetone/IPA producer (Deepak Phenolics, Dahej) whose earnings are driven by the spread between benzene/propylene feedstock costs and phenol/acetone/IPA realizations — a cyclical, petrochemical-style commodity business, but one with a structural moat as the dominant domestic producer in an import-dependent market, with India-landed import parity pricing and logistics advantages.

  2. A specialty/fine-chemical intermediates business (Advanced Intermediates, standalone DNL) with leading positions in niche molecules (sodium nitrite, nitro-toluenes, xylidines, cumidines, oximes, fuel additives, DASDA/OBA). This business is more specialty in nature but has been under severe pressure since FY2024 from Chinese oversupply and dumping, with EBIT margins collapsing from ~16% (FY24) to ~3–8% in recent quarters.

Overlaying these is a third, emerging business — advanced materials (polycarbonate compounding via Deepak Advanced Materials, and the forthcoming polycarbonate resin and BPA plants via Deepak Chem Tech) — which is pre-revenue at scale but will dominate capital allocation through FY2029.

Business and revenue model

DimensionCharacterization
Revenue type~100% product sales (manufactured chemicals). No material service, subscription or licensing revenue.
PricingLargely spot/contract pricing linked to international benchmarks and import parity (Phenolics); negotiated contract pricing with key accounts, often with raw-material pass-through mechanisms (AI).
Customer typesAgrochemical formulators/AI makers, dye & pigment makers, pharma API makers, rubber chemical makers, paper & detergent makers (OBA), laminates/resin makers (phenol), solvent/pharma users (acetone, IPA), and future polymer converters (PC).
Geographic mix~85% domestic / ~15% export (Q1 FY27 consolidated). AI is ~50:50 domestic/export; Phenolics is almost entirely domestic (management, Q1 FY27 call).
Value-chain positionUpstream-to-midstream. Backward integration is a strategic priority: in-house nitric acid (commissioned December 2025), propylene and hydrogen via a 15-year Petronet LNG pipeline agreement, HyCO via Praxair (Linde). Forward integration into MIBK/MIBC, acetophenone, BPA and polycarbonate.
End-marketsAgrochemicals, colorants (dyes & pigments), pharmaceuticals, rubber, plastics & laminates, paper, textiles, home & personal care, paints & coatings, construction chemicals, automotive/electronics (via PC), energy (fuel additives).

Legal-entity structure (group)

EntityOwnershipRoleSource
Deepak Nitrite Limited (DNL)Listed parentAdvanced Intermediates manufacturing (Nandesari, Roha, Taloja, Hyderabad and other sites)Company filings
Deepak Phenolics Limited (DPL)100%Phenol, acetone, IPA at Dahej; existing capacity 330 KTA phenol, 200 KTA acetone, 80 KTA IPACompany press releases (Apr 2025)
Deepak Chem Tech Limited (DCTL)100% (equity); preference capital held by DNL and DPLGrowth-project vehicle: nitric acid, fluorination, MIBK/MIBC, acetophenone, chlorination, new phenol/acetone/IPA, BPA and polycarbonate; incorporated 9 October 2020Moneycontrol, ScanX, company filings
Deepak Advanced Materials Limited (DAML)100%Polycarbonate and engineering-polymer compounding at Manjusar, Savli (Vadodara)Company press release
Deepak Nitrite Corporation Inc. (USA)100%Overseas trading/marketing subsidiaryICRA rationale (Aug 2025)
Oman entity ("DN Oman")Referenced by ICICI Securities (Apr 2025) as a project in commissioning——

Strategy

Stated strategic themes (paraphrased from FY2026 presentation, calls and press releases)

  1. Integration as resilience. Build backward integration (nitric acid, propylene/hydrogen via pipeline, HyCO) and forward integration (MIBK/MIBC, acetophenone, BPA, PC) so that margins are less exposed to traded-intermediate volatility. The CMD has stated that once the integrated projects are complete, Deepak will be among the world's largest single-site phenol/acetone producers, with over half of capacity converted into derivatives such as BPA and PC resins.

  2. Import substitution / "Make in India." Target molecules where India is structurally import-dependent (phenol, acetone, MIBK, BPA, polycarbonate), aligned with Atmanirbhar Bharat and leveraging Dahej PCPIR infrastructure.

  3. Responsible Chemistry. Transition toward 60–70% renewable energy, green chemistry, effluent recycling (MVR, ASP/MBR), and circularity.

  4. From intermediates supplier to "fit-for-effect" partner. Move up the value chain toward formulated compounds and engineering polymers for marquee end-customers.

  5. Domestic-first growth. Lean on resilient Indian demand while export markets face Chinese oversupply.

Strategic initiatives register (last ~24 months)

DateInitiativeInvestmentStatus
Nov 2024Polycarbonate resin project (165 KTA, Dahej) with Trinseo licence and asset purchase~INR 5,000 Cr initially; now part of ~INR 11,500 Cr integrated propylene-to-PC programme~INR 1,200 Cr spent by Q1 FY27; commissioning H2 FY28–FY29
c. Mar 2025PC compounding (DAML)—Operating
Apr 2025New phenol (300 KTA), acetone (185 KTA), IPA (100 KTA) complex (DCTL)~INR 3,500 CrUnder execution; timed to Petronet's propane dehydrogenation propylene supply
2024–2515-year Petronet LNG propylene (250 KTPA) and hydrogen (11 KTPA) supply—Contracted
Oct 2025DRDC 2.0 R&D centre—Operating
Dec 2025Nitric acid plant (DCTL, Nandesari)~INR 515 CrOperating
May 2026HyCO plant agreement with Praxair India (Linde)Third-party build-own-operate (terms undisclosed)Targeted 2028
Apr–Aug 2026Leadership restructuring (Deputy MDs, CEO-AI, ED & CMO, new independents)—Effective
Aug 2026MIBK/MIBC and acetophenone (DCTL, Dahej)~INR 735 CrCommissioned 6 Aug 2026
Aug 2026BPA plant 240 KTA (DCTL)~INR 2,500 CrApproved 4 Aug 2026
Q2 FY27Multipurpose agrochemical intermediates facility—Guided for commissioning in Q2 FY27
Sep 2026Chlorination & specialty chemical plant (DCTL, Dahej)~INR 300 CrCommissioned 29 Sep 2026
OngoingRenewable energy investments—~INR 4.5 Cr savings in Q1 FY27; ~INR 20 Cr annualized expected

Medium-term targets and guidance

ItemGuidanceSource
Capex FY2026~INR 1,200–1,300 CrQ3 FY26 commentary (TradeBrains)
Capex FY2027~INR 2,500 CrSame
PC programme funding~60:40 debt:equity; debt tied upQ1 FY27 call
Peak group debtINR 8,000–8,500 Cr incl. working capital; D/E < 1xManagement, reported Sep 2026
Propylene-based run rate~100 KT annualized currently; debottlenecking toward ~400 KT short-to-medium term (as reported by ZoomInfo summary; interpret with caution)Q1 FY27 call summary
PC/BPA commissioningPC H2 FY2028–FY2029; BPA a couple of months afterQ1 FY27 call
Explicit revenue/margin targets——

Products & Services

DNL does not publish list prices; pricing is contract- or spot-based and not disclosed. Launch years are given where known.

Advanced Intermediates

Product / lineDescription & applicationsTarget customersPosition / notes
Sodium nitriteInorganic intermediate for dyes, pharma, rubber chemicals, meat curing, heat-transfer salts, corrosion inhibitionDye makers, pharma, rubber chemicals, metal treatmentIndia's largest producer; aggregator cites ~75% domestic share across sodium nitrite/nitrate/nitro-toluenes. Original 1972 product
Sodium nitrateExplosives, glass, fertilizer and heat-transfer applicationsIndustrial usersCo-product with sodium nitrite
Nitro-toluenes (ONT, PNT, MNT)Nitration of toluene; precursors for toluidines, dyes, agrochemicalsDye and agro intermediates makersMarket leader in India
Nitro-toluidinesDownstream amines for pigments and agro AIsPigment and agro makers—
XylidinesAromatic amines for agrochemicals (e.g., herbicides/fungicides) and pharmaGlobal agrochemical majorsRanked among top 3 global producers
CumidinesAmines for herbicides and specialty usesAgrochemical makersAmong top 3 globally
OximesAnti-skinning agents in paints; agro intermediatesPaint and agro customersAmong top 3 globally
Fuel additivesCetane improvers and related additives (e.g., nitrate-based)Refiners, fuel marketersMarket leader domestically (ICRA)
Specialty agrochemical intermediatesMulti-step intermediates; new multipurpose agro-intermediates facility commissioned in Q2 FY27 (management guidance)Agro innovators and genericsUnder pricing pressure from China
Optical Brightening Agents (OBA)Fluorescent whitening agents for paper, detergents, textiles; a new OBA variant introduced in FY2025Paper mills, detergent makersPart of former Performance Products
DASDA (diamino stilbene disulfonic acid)Key intermediate for OBAsOBA makersAcquired 2006 (Vasant Chemicals); Hyderabad
Benzotrifluoride and fluorinated intermediatesFluorination chemistry for agro/pharmaAgro and pharma makersDCTL's first fluorination plant at Dahej (~INR 220 Cr fluorochemicals capex referenced)
Nitric acid (weak and concentrated)Captive feedstock for nitration; enables supply securityCaptive (DNL standalone)~INR 515 Cr plant, Nandesari; operations began December 2025; designed to meet DNL's full requirement (~70 KTPA referenced by ICICI Securities)
Chlorination & specialty chemicalsNew chlorination-based derivativesAgro, pharma~INR 300 Cr DCTL plant, Dahej; commissioned 29 September 2026
Hydrogenation / photo-chlorination productsAmine and chlorinated derivativesAgro, pharma, dyesProjects referenced by HDFC Securities (Jan 2025); status of each not individually verified

Phenolics

ProductCapacityApplicationsPosition
Phenol330 KTA (DPL, Dahej); +300 KTA approved at DCTLPhenolic resins, laminates, BPA, alkyl phenols, agro, pharma~50% domestic market share; company calls its plant one of the lowest thermal-footprint phenol plants globally (company claim)
Acetone200 KTA (DPL); +185 KTA approvedSolvents, pharma, MIBK/MIBC, BPALargest Indian producer
Isopropyl alcohol (IPA)80 KTA (DPL); +100 KTA approvedPharma solvent, sanitizers, coatingsCommissioned 2020; pharma-grade
MIBK (methyl isobutyl ketone)Not disclosed (~INR 735 Cr MIBK/MIBC plant)Solvent for paints, rubber antioxidant precursorCommissioned 6 August 2026 (DCTL)
MIBC (methyl isobutyl carbinol)—Mining flotation frother, solventsCommissioned August 2026; pre-commissioning runs reportedly exceeded design capacity
Acetophenone—Fragrances, resins, pharmaCommissioned August 2026; recovered from phenol process residues (industry-first claim)

Advanced Materials (emerging)

Product / projectDescriptionStatus
Polycarbonate compoundsCustomizable PC granules and engineering-polymer compounds in multiple grades and colours for automotive/e-mobility, electronics, construction, appliances, medical, aerospaceDAML plant, Manjusar/Savli; inaugurated c. March 2025
Polycarbonate resin165 KTA plant at Dahej using Trinseo interfacial polymerization technology and relocated Stade (Germany) equipment; access to CALIBRE resin brandUnder construction; commissioning targeted H2 FY2028–FY2029 (originally Q4 FY2028)
Bisphenol A (BPA)240 KTA greenfield plant; captive feed to PC plus merchant sales to epoxy resin makersApproved 4 August 2026 (~INR 2,500 Cr); commissioning a few months after PC

Financial Narrative

Income statement (consolidated, INR Cr)

Sources: company press releases and presentations (FY22, FY23, FY24, FY25, FY26); operating profit excl. other income from Screener; FY22–FY23 EPS derived (PAT ÷ 13.64 Cr shares).

Gross profit: Not separately reported by DNL (Indian GAAP format). StockAnalysis reports TTM (June 2026) gross profit of INR 2,234 Cr.

Margins

Derived from 6.1.

Growth

Note on FY2021 PAT: Business Standard reported INR 775.81 Cr; Screener-derived series implies ~INR 757 Cr. Discrepancy likely reflects minority/OCI treatment.

Quarterly trajectory (consolidated, INR Cr)

Sources: company releases; Screener for EPS; Q1 FY26 EBITDA derived from Q1 FY27 +159% YoY.

Sources: Net worth FY22 from company press release; total assets from Moneycontrol; borrowings from TradeBrains (FY24 INR 286 Cr; FY26 INR 1,638 Cr); net cash/debt from StockAnalysis. Conflicts: MarketsMojo reports total debt of INR 1,025.71 Cr at March 2026 (vs INR 1,638 Cr); Tijori reports net debt of INR 990 Cr (Mar-26) and INR 358 Cr (Mar-25) vs StockAnalysis INR 1,176 Cr and INR 355 Cr; Simply Wall St reported March 2024 debt of INR 217 Cr with INR 585 Cr cash. Goodwill is believed immaterial (no large acquisitions), but the PC technology licence and Trinseo assets will add intangibles/CWIP.

Cash flow (INR Cr)

Sources: StockAnalysis (aggregator). Dividends paid approximated as INR 7.5 × 13.64 Cr shares for the prior year's final dividend. No buybacks have been announced.

Ratios

Additional data points (various dates, aggregator-sourced): ROE ~12.8% average over the last three years (Screener); TTM ROIC 11.5% (StockAnalysis); five-year average ROCE ~29% and ROE ~21% (MarketsMojo); management cited ROCE of ~15% in Q3 FY26 commentary (TradeBrains). Net debt/EBITDA FY2026 ≈ 1.1x (INR 1,176 Cr ÷ INR 1,041 Cr; derived). Asset turnover FY2025 ≈ 1.07x (INR 8,282 Cr ÷ INR 7,717 Cr; derived).

Commentary on trends, inflections and drivers

FY2022 — cyclical peak. Revenue grew 56% and EBITDA reached INR 1,646 Cr (24% margin) as phenol, acetone and IPA realizations stayed elevated after COVID-era supply disruptions and the phenol plant ran at high utilization. PAT of INR 1,067 Cr remains the group's high-water mark, and the balance sheet was net-cash.

FY2023–FY2025 — margin normalization and AI erosion. Revenue held around INR 7,700–8,300 Cr but EBITDA fell each year, from INR 1,337 Cr to INR 1,176 Cr. Two separate forces were at work: (i) phenolic spreads normalized from abnormal FY2022 levels, with Phenolics EBIT margins stabilizing around 13%; and (ii) the AI segment was hit by Chinese dumping, destocking in agrochemicals and weak European demand, sending its EBIT from INR 446 Cr (FY24, incl. insurance) to INR 176 Cr (FY25). Phenolics volume growth (+16% revenue in FY25) partly offset this.

FY2026 — trough. Revenue fell 5% to INR 7,887 Cr and PAT 21% to INR 551 Cr. Management attributed the weakness to crude-linked supply-chain disruption, pricing pressure and geopolitical uncertainty. Q2 and Q3 FY26 were the low points (EBITDA margins ~11%), before Q4 recovered to 18%.

Q1 FY2027 — sharp inflection. EBITDA of INR 554 Cr (21% margin) and PAT of INR 345 Cr were all-time quarterly records. Drivers cited: strong domestic phenol/acetone demand and realizations, proactive feedstock sourcing during volatile propylene markets, debottlenecked phenol volumes, renewable-energy savings (~INR 4.5 Cr in the quarter), and nitric-acid backward integration in AI. Management noted propylene supply constraints and a short maintenance shutdown limited throughput during the quarter.

Cash flow and leverage — structural shift. FCF turned negative in FY2025 and FY2026 as capex rose to INR 1,100–1,200 Cr a year, moving the group from net cash (FY24) to net debt (~INR 1,000–1,200 Cr at FY26). Management guides peak debt of INR 8,000–8,500 Cr including working capital, with debt/equity kept below 1x, and has said FY2027 capex will be roughly INR 2,500 Cr. Interest costs are rising (INR 23 Cr in Q1 FY27 vs INR 8 Cr in Q1 FY26), though much interest on projects is capitalized during construction — Screener flags possible interest capitalization. The cash conversion cycle has lengthened from 67 to 92 days over FY2022–FY2026, a working-capital watch point.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentWhat it containsKey productsPrincipal entity

Advanced Intermediates (AI)

Legacy DNL businesses formerly reported as Basic Chemicals, Fine & Speciality Chemicals and Performance Products

Sodium nitrite, sodium nitrate, nitro-toluenes, nitro-toluidines, xylidines, cumidines, oximes, fuel additives, specialty agrochemical intermediates, optical brightening agents (OBA), DASDA, benzotrifluoride; plus new DCTL products (nitric acid, fluorination/chlorination/hydrogenation derivatives)

DNL standalone; DCTL

Phenolics

Cumene-based phenol chain

Phenol, acetone, isopropyl alcohol (IPA); from August 2026 MIBK, MIBC, acetophenone (reporting allocation to be confirmed in Q2 FY27)

Deepak Phenolics; DCTL

Revenue by Segment

Segment (INR Cr)FY2022FY2023FY2024FY2025FY2026

Advanced Intermediates revenue (INR Cr)

2,5113,0342,7242,5272,553

Phenolics revenue (INR Cr)

4,3034,9715,0035,8055,401

Inter-segment elimination (INR Cr)

-12-32-46-50-67

Consolidated revenue from operations (INR Cr)

6,8027,9727,6828,2827,887

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment EBIT (INR Cr)

Segment EBIT (INR Cr)FY2024FY2025

Advanced Intermediates EBIT (INR Cr)

446176

Phenolics EBIT (INR Cr)

644783

AI EBIT margin (%)

167

Phenolics EBIT margin (%)

1313

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2024FY2025FY2026

AI revenue growth YoY (%)

-10-71

Phenolics revenue growth YoY (%)

116-7

AI share of gross segment revenue (%)

353032

Phenolics share of gross segment revenue (%)

657068

Segment Overview — Advanced Intermediates

SegmentRevenue (INR Cr)YoYQoQEBIT (INR Cr)EBIT margin

Advanced Intermediates

803.85+33%+14%66.988%

Phenolics

1,775.05+36%+24%417.76

24% (vs 9% in Q1 FY26)

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

6,8027,9727,6828,2827,887

Total income incl. other income (INR Cr)

6,8458,0207,7588,3667,947

EBITDA as reported by company (INR Cr)

1,6461,3371,1991,1761,041

Operating profit excl. other income (INR Cr)

1,6071,2921,1271,095987

Profit before tax (INR Cr)

1,4341,1461,102953757

Net profit / PAT (INR Cr)

1,067852811697551

EPS basic & diluted (INR)

78.262.559.4551.1240.36

Dividend per share (INR)

———7.57.5

Margin (%)

Margin (%)FY2022FY2023FY2024FY2025FY2026

EBITDA margin on total income (%)

24.016.715.514.113.1

Operating margin excl. other income (%)

23.616.214.713.212.5

PBT margin (%)

21.114.414.311.59.6

Net margin on revenue (%)

15.710.710.68.47.0

Valuation Snapshot

MetricValue

Revenue CAGR FY2021–FY2026 (INR 4,360 Cr → 7,887 Cr)

~12.6%

Revenue CAGR FY2022–FY2026

~3.8%

PAT CAGR FY2021–FY2026 (INR 776 Cr → 551 Cr)

~−6.6%

TTM (to June 2026) revenue

INR 8,575 Cr (+7.1% YoY)

TTM PAT

INR 783 Cr

Income Statement and Per-Share Data (Quarterly)

MetricQ1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue from operations (INR Cr)

1,8901,9021,9752,1202,578

Total income (INR Cr)

1,914—1,9832,1272,592

EBITDA (INR Cr)

214—219383554

PAT (INR Cr)

112119100220345

EPS (INR)

8.238.707.3216.1125.30

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

——6,0967,717—

Net worth / equity (INR Cr)

3,338————

Total borrowings (INR Cr)

——286—1,638

Net cash (+) / net debt (−) (INR Cr)

162342297-355-1,176

Equity share capital (INR Cr)

2727272727

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

824650874625539

Capital expenditure (INR Cr)

1873587381,1221,185

Free cash flow (INR Cr)

637292136-497-646

Dividends paid (INR Cr, approx.)

———102102

Share buybacks (INR Cr)

00000

Working Capital (Days) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

Cash conversion cycle (days)

6776778292

Debt/equity (x)

———0.220.28

Interest coverage TTM Jun-26 (x)

————18.3

Revenue by Region and Revenue by Region (%)

Region (INR Cr)FY2024FY2026

India domestic revenue (INR Cr)

6,1356,791

Export revenue (INR Cr)

1,5471,156

Domestic share (%)

8085

Export share (%)

2015

Segment Overview (2)

SegmentDomesticExport

Advanced Intermediates

~50%

~50%

Phenolics

~100%

Negligible

Valuation Snapshot — Price

MetricValueSource

Price (NSE)

INR 1,492.80

Multiple

52-week high / low

INR 1,897.90 / INR 1,280.00 (one source cites high of INR 1,904.4)

Dhan, IIFL, Investing.com

1-month return

−15.3%

Dhan

3-month return

−3.5%

Dhan

1-year return

−18.65%

Dhan / ICICI Direct

3-year return

−29.6%

Dhan

5-year return

−38.0%

Dhan

50 / 200 DMA

~INR 1,647–1,679 / ~INR 1,633–1,683

5paisa, Dhan

Index membership

Nifty Midcap 150 (per 2025 Moneycontrol report)

Moneycontrol

Market Valuation

Metric20212022202320242025

Year-end market cap (INR Bn)

339.6270.8338.6340.1234.2

Valuation Multiples

MultipleDeepak NitriteNotes

P/E (TTM, on INR 783 Cr TTM PAT)

~26x

Several sites still display ~88–98x using stale standalone EPS — ignore

EV/EBITDA (TTM)

~16.1x

StockAnalysis

EV/Sales (TTM)

~2.5x

StockAnalysis

P/B

~3.3–3.6x (conflicting sites show 6.3–7.5x using standalone book)

5paisa, Dhan

Dividend yield

~0.5%

Multiple

Analyst Ratings & Targets

BrokerDateRatingTargetBasis

ICICI Securities

15 Apr 2025

ADD

INR 2,120

30x FY27E P/E

JM Financial

29 May 2025

Not captured

Not captured

Forecast FY27E EBITDA INR 1,705 Cr, FY28E INR 1,959 Cr

HDFC Securities

Feb 2025

Company update

Not captured

PC entry thesis

MarketScreener consensus

Various

Historically "Outperform"

——

Per-Share Data

MetricFY2021FY2025FY2026

Dividend per share (INR)

5.57.57.5

Group Entities

EntityAgencyRatingOutlookDate

Deepak Nitrite Ltd

ICRA

[ICRA]AA / [ICRA]A1+ (INR 490 Cr bank lines; earlier also INR 200 Cr CP)

Stable (from Positive)

Aug 2025

Deepak Nitrite Ltd

CRISIL

CRISIL AA / A1+ (INR 750 Cr)

Stable

—

Deepak Phenolics Ltd

ICRA

AA / A1+

—

Mar 2024

Deepak Chem Tech Ltd

ICRA

A / A2+

Positive (Mar 2024)

—

Moody's / S&P / Fitch

—

Not rated

——

Analyst Conclusions

Management guidance (latest)

  • Commission the remaining Q2 FY27 projects (multipurpose agro-intermediates facility) after MIBK/MIBC/acetophenone (Aug 2026) and chlorination (Sep 2026).

  • Debottleneck phenol and align new phenol capacity with Petronet's propylene supply.

  • PC commissioning H2 FY2028–FY2029; BPA a few months later; total PC programme ~INR 11,500 Cr funded ~60:40 debt:equity.

  • FY2027 capex ~INR 2,500 Cr; peak debt INR 8,000–8,500 Cr; D/E below 1x.

  • No explicit revenue or EBITDA guidance.

Consensus growth expectations

Earlier broker models (JM Financial, May 2025) projected EBITDA growth to ~INR 1,705 Cr in FY2027 and ~INR 1,959 Cr in FY2028. Annualizing Q1 FY27 EBITDA (INR 554 Cr) gives ~INR 2,200 Cr, but this should not be treated as guidance given spread volatility.

Bull case

  1. Phenolics operating leverage is real and repeatable: Q1 FY27 Phenolics EBIT of INR 418 Cr (24% margin) on INR 1,775 Cr revenue shows what full utilization plus integration yields; phenol capacity doubling adds volume on the same platform.

  2. New derivatives broaden the earnings base: MIBK/MIBC, acetophenone, chlorination and the multipurpose agro plant come online in FY2027, adding value to captive acetone and diversifying AI.

  3. Valuation already discounts a lot: at ~26x TTM P/E and ~16x EV/EBITDA with the stock 38% below its five-year level, a sustained recovery to ~INR 1,800–2,000 Cr EBITDA plus a credible PC narrative could re-rate the shares.

Bear case

  1. Q1 FY27 may be a spread spike, not a new base: Phenolics EBIT margin swung from 9% to 24% within a year; FY2026 full-year PAT was only INR 551 Cr.

  2. Capex dwarfs current earnings power: ~INR 11,500 Cr PC programme plus ~INR 2,500 Cr BPA versus FY26 OCF of INR 539 Cr; FCF negative for two years; peak debt of INR 8,000–8,500 Cr arrives before PC earnings.

  3. AI segment may not recover: export revenue down 25% in two years and Q3 FY26 AI margin near 2%; Chinese overcapacity is structural, and global PC/BPA oversupply could hit returns on the new assets.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timing
Q2 FY27 results — sustainability of 20%+ EBITDA margin~Nov 2026
Ramp-up utilization of MIBK/MIBC/acetophenone and chlorination plantsQ3–Q4 FY27
Phenol/acetone spread trajectory and propylene availabilityOngoing
AI segment EBIT margin trend (target: return to double digits)Each quarter
PC project milestones (Stade equipment relocation, civil works, licensor sign-offs)Through FY2027
BPA/phenol technology licensor announcementsUnconfirmed timing
Net debt build and any credit-rating outlook changeFY2027
Trade-remedy decisions on phenol/acetone/intermediatesEvent-driven
Governance: remuneration and board independence developments2027 AGM

Analyst verdict

Deepak Nitrite sits at the most consequential juncture in its 56-year history. The company that earned INR 1,067 Cr in FY2022 saw profits roughly halve by FY2026 as two forces converged: normalization of abnormal phenol spreads and a structural assault on its legacy Advanced Intermediates business from Chinese overcapacity. Q1 FY2027 then delivered the best quarter on record, proving that the Phenolics platform, once integrated and running full, can generate margins in the mid-20s at the EBIT level. The central analytical question is whether that quarter marks a new earnings floor or a cyclical peak.

The evidence supports a more cautious middle reading. Integration benefits — captive nitric acid, contracted pipeline propylene, and new acetone derivatives — are durable and should lift the through-cycle margin above the FY2025–FY2026 trough of 13–14% EBITDA. But Phenolics remains a spread business, AI is still earning single-digit margins, and the group is entering a heavy-investment phase in which debt could rise roughly five- to six-fold before the polycarbonate and BPA assets contribute, now not before H2 FY2028–FY2029.

The strategic logic of a cumene-to-polycarbonate chain in an import-dependent Indian market is sound, and DNL's Dahej execution record lends credibility. Yet the size of the bet relative to current cash generation, the slippage already visible in PC timelines, global PC/BPA overcapacity, and governance signals (combined CMD role, family executive concentration, AGM dissent) justify a risk premium.

At ~26x trailing earnings and ~16x EV/EBITDA after a ~38% five-year share-price decline, the market is pricing partial recovery, not the full integration thesis. We would characterize the stock as a long-duration execution story with near-term earnings momentum.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleSince / tenureBackground

Deepak C. Mehta

Chairman & Managing Director

Long-tenured promoter-CMD (several decades)

Promoter; holds 16.56% directly (June 2026). Also associated with Deepak Fertilisers & Petrochemicals group entities that appear in promoter group

Maulik D. Mehta

Deputy Managing Director (from 9 May 2026, five-year term); previously Executive Director & CEO (since June 2020); also ED & CEO of Deepak Chem Tech

~16+ years in group

BBA (University of Liverpool); Master's in Industrial & Organisational Psychology (Columbia University); Owner/President Management programme (Harvard Business School). Leads major project execution and ESG agenda

Meghav D. Mehta

Deputy Managing Director (from 9 May 2026, five-year term)

Previously non-executive director; director of DCTL

Signed Gujarat government MoU on behalf of DCTL

Sanjay Upadhyay

Director (Finance) & Group CFO

Re-appointed for five years from 1 August 2026

Long-standing group CFO

Anant Pande

Executive Director & Chief Marketing Officer

Three years from 5 August 2026

Appointed at 55th AGM

Lohit Shringi

CEO — Advanced Intermediates Business

Appointed 4 August 2026 (KMP/senior management, not board)

—

Arvind Bajpai

Company Secretary

—

Signs exchange communications

Governance Overview

AttributeDetail

Board size

13 directors

Executive directors

5 (Deepak C. Mehta, Maulik Mehta, Meghav Mehta, Sanjay Upadhyay, Anant Pande — composition inferred from appointments; verify against filing)

Recent exits

Dileep Choksi (independent) ceased 7 August 2026 on completion of second term

Chair/CEO separation

No — the Chairman is also Managing Director, and three executive seats are held by the promoter family

Major Shareholders

Holder category%

Promoter & promoter group

49.34

Mutual funds

11.45

Insurance companies

~10.3 (April 2026 data)

Total DII

23.8

FII/FPI (154 FIIs)

6.24

Retail & others

~20.6

Promoter pledge

0

Major Shareholders by Holder

HolderStake (%)As of

Deepak Chimanlal Mehta (promoter)

16.56

Jun 2026

Deepak Novochem Technologies Ltd (promoter entity)

3.41

2025–26

Kotak Mahindra Mutual Fund (all schemes)

3.36

Jun 2026

Franklin Templeton Mutual Fund

2.67

Jun 2026

Nippon India Mutual Fund

1.86

Jun 2026

ICICI Prudential Mutual Fund

1.29

Jun 2026

Sundaram Mutual Fund

0.78

Jun 2026

Investor Education & Protection Fund

0.502,026

Canara Robeco Mutual Fund

0.38

Jun 2026

Mirae Asset Mutual Fund

0.30

Jun 2026

Competitive Landscape

Competitors by Segment

SegmentCompetitorCountryOverlapRelative positioning

Phenolics

Hindustan Organic Chemicals (HOCL)

India

Phenol/acetone (Kochi)

Small, state-owned; DNL is the dominant domestic producer

Phenolics

Imports from Korea, Taiwan, Thailand, China, Singapore, Saudi Arabia (e.g., Kumho P&B, PTT Global Chemical, Mitsui Chemicals, INEOS Phenol, Chinese producers)

Global

Phenol, acetone

—

Phenolics (IPA/solvents)

Deepak Fertilisers & Petrochemicals (IPA), Chemplast and others

India

IPA

Promoter-group-related entity also produces IPA (verify overlap)

Phenolics derivatives (MIBK/MIBC)

—

Global

MIBK/MIBC

New entrant domestically

Advanced Intermediates

Aarti Industries

India

Nitro-chlorobenzenes, nitro-aromatics, agro/pharma intermediates

Larger, more export-oriented

Advanced Intermediates

Atul Ltd

India

Aromatics, intermediates, crop protection

Diversified specialty peer

Advanced Intermediates

Vinati Organics

India

Specialty intermediates (IBB, ATBS)

Higher-margin niche player

Advanced Intermediates

Navin Fluorine

India

Fluorinated intermediates

Competes with DCTL's fluorination ambitions

Advanced Intermediates

Clean Science & Technology

India

Performance chemicals

High-margin niche

Advanced Intermediates

Laxmi Organic, Sudarshan Chemical, Bodal Chemicals, Meghmani

India

Acetyls, pigments, dyes intermediates

Partial overlaps

Advanced Intermediates

Chinese nitration/amine producers

China

Xylidines, nitro-toluenes, sodium nitrite, OBA

Primary source of FY24–FY26 price pressure

Advanced Intermediates (OBA)

Global OBA producers (e.g., Archroma, Chinese producers)

Global

OBA/DASDA

—

Advanced Materials (PC/BPA)

Covestro, SABIC, Lotte Chemical, Mitsubishi Chemical, Chinese PC producers; domestic: none at scale

Global

PC resin, BPA

DNL would be first large Indian PC resin producer

Peer Comparison FY2026

MetricDeepak NitriteAarti IndustriesAtul LtdNavin FluorineVinati Organics

Revenue FY26 (INR Cr)

7,8879,0186,2743,3792,227

Revenue growth FY26 (%)

-512—410

PAT FY26 (INR Cr)

551419689664444

Net margin FY26 (%)

7.04.611.019.619.9

EBITDA FY26 (INR Cr)

1,0411,172———

Company Snapshot

$910.7M

Revenue

5,000

Employees

$2,100M

Market Cap

1970

Founded

Gujarat, India

Headquarters

SWOT Analysis

Strengths

  • Dominant domestic phenol franchise: ~50% Indian phenol/acetone share; Phenolics revenue grew from INR 4,303 Cr (FY22) to INR 5,805 Cr (FY25).
  • Record profitability capability demonstrated: Q1 FY27 EBITDA INR 554 Cr (21% margin) and Phenolics EBIT margin 24% — showing operating leverage at high utilization.
  • Niche global leadership in AI molecules: top-3 global producer of xylidines, cumidines and oximes; largest Indian sodium nitrite producer.
  • Backward integration delivered: nitric acid plant (~INR 515 Cr) operating since December 2025; AI EBIT doubled QoQ in Q1 FY27 partly on integration benefits.
  • Feedstock security: 15-year Petronet LNG pipeline agreement for 250 KTPA propylene and 11 KTPA hydrogen.
  • Investment-grade domestic credit: ICRA AA (Stable)/A1+; interest coverage ~18x TTM.
  • Strong historical capital efficiency: five-year average ROCE ~29% and ROE ~21% (MarketsMojo), and an FY2022 net-cash balance sheet with INR 3,338 Cr net worth.

Weaknesses

  • AI segment margin collapse: AI EBIT fell from INR 446 Cr (FY24) to INR 176 Cr (FY25); Q3 FY26 AI EBIT was INR 15 Cr.
  • Earnings decline FY22–FY26: PAT fell from INR 1,067 Cr to INR 551 Cr; EPS from ~INR 78 to INR 40.36.
  • Negative free cash flow: FCF of −INR 497 Cr (FY25) and −INR 646 Cr (FY26) per StockAnalysis.
  • Lengthening working-capital cycle: cash conversion cycle up from 67 days (FY22) to 92 days (FY26).
  • Export erosion: export revenue down from INR 1,547 Cr (FY24) to INR 1,156 Cr (FY26).
  • Concentrated earnings source: Phenolics contributed ~86% of Q1 FY27 segment EBIT, making group profits hostage to phenol/acetone spreads.

Opportunities

  • Polycarbonate import substitution: 165 KTA PC plant would make DNL the first large-scale Indian PC resin producer, backed by Trinseo technology and CALIBRE brand access.
  • BPA merchant sales: 240 KTA BPA plant targets epoxy-resin demand in addition to captive use.
  • Phenol capacity doubling: additional 300 KTA phenol, 185 KTA acetone, 100 KTA IPA approved (~INR 3,500 Cr).
  • New derivatives ramp: MIBK/MIBC/acetophenone (commissioned Aug 2026) and chlorination plant (Sep 2026) add value-added volumes in FY2027–FY2028.
  • China+1 supply-chain realignment: management noted export customers seeking India-based supply chains.
  • Renewable energy cost savings: ~INR 20 Cr annualized savings expected; transition target of 60–70% renewables.

Threats

  • Chinese overcapacity and dumping — explicitly cited for AI pricing pressure in Q3 FY26.
  • Global PC/BPA oversupply — large Chinese capacity additions could compress spreads before DNL's plants start in FY2028–FY2029 (industry risk; not quantified).
  • Execution and timeline drift: PC commissioning moved from "Q4 FY2028" (Nov 2024 announcement) to "H2 FY2028–FY2029" (Aug 2026).
  • Leverage build-up: peak debt guided at INR 8,000–8,500 Cr versus ~INR 1,000–1,600 Cr at FY26 end; ICRA flags net debt/OPBITDA >1.5x sustained as a downgrade trigger.
  • Feedstock volatility and availability: Q1 FY27 throughput was impacted by raw-material sourcing challenges.
  • Process-safety incidents: the June 2022 Nandesari fire disrupted sodium nitrite output for months; hazardous chemistries (nitration, phosgene for PC) carry inherent risk.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
10 Apr 2025DCTL board approved ~INR 3,500 Cr phenol/acetone/IPA complex at DahejDoubles phenol capacity; feeds PC chain
15 Apr 2025ICICI Securities initiated coverage with ADD, target INR 2,120 (30x FY27E P/E)Sell-side framing of capex story
28 May 2025Q4 FY25: revenue INR 2,180 Cr, PAT INR 202 Cr (−20% YoY); FY25 PAT INR 697 Cr (−14%); INR 7.50 dividendPhenolics strong, AI weak; government incentives aided EBITDA (JM Financial)
Aug 2025ICRA reaffirmed AA/A1+ but revised outlook to Stable from PositiveReflects capex-driven leverage build
Aug 2025Q1 FY26: revenue INR 1,890 Cr, PAT INR 112 Cr (−45% YoY)Trough begins; concentrated nitric acid in trial production
19 Sep 2025DCTL issued INR 48 Cr OCRPS to DPLIntra-group funding of projects
Oct 2025DRDC 2.0 R&D centre inaugurated at SavliInnovation capacity
Nov 2025Q2 FY26: revenue INR 1,902 Cr (−6.4%), PAT INR 119 Cr (−39%)Continued AI pressure
Dec 2025DCTL nitric acid plant (~INR 515 Cr) began operations, NandesariBackward integration for AI
Feb 2026Q3 FY26: total income INR 1,983 Cr (+3%), EBITDA INR 219 Cr (+16%), PAT INR 100 Cr; AI EBIT INR 15 CrAI margin near breakeven amid Chinese dumping
Mar 2026Management guided FY27 capex ~INR 2,500 CrCapex acceleration
3 Apr 2026Board approved Deputy MD elevations, CFO re-appointment, new independent directorsSuccession and governance refresh
c. May 2026DCTL–Praxair (Linde) HyCO agreementSecures PC feedstock
15 May 2026Q4 FY26: revenue INR 2,127 Cr, EBITDA INR 383 Cr (+74% QoQ), PAT INR 220 Cr; FY26 PAT INR 551 Cr; INR 7.50 dividend; PC target cited as June 2028Recovery begins
4 Aug 2026Q1 FY27 record: revenue INR 2,592 Cr (+35%), EBITDA INR 554 Cr (+159%), PAT INR 345 Cr (+207%)Strongest quarter in company history
4 Aug 2026DCTL approved ~INR 2,500 Cr, 240 KTA BPA plantCompletes cumene-to-PC chain
4 Aug 2026Lohit Shringi appointed CEO-Advanced IntermediatesDedicated leadership for struggling segment
5 Aug 202655th AGM: dividend approved; Anant Pande appointed ED & CMO; ~12% institutional dissent on Deputy MD resolutionGovernance scrutiny on promoter-family pay/roles
5 Aug 2026Shares opened ~7% higher post-results; closed ~INR 1,751Market endorsement of inflection
6 Aug 2026MIBK/MIBC plant (~INR 735 Cr) commissioned at Dahej, alongside acetophenoneFirst major Phenolics derivatives online
7 Aug 2026Milin Mehta and Adnan Ahmad joined as independent directors; Dileep Choksi exitedBoard refresh
Aug 2026Management updated PC programme: ~INR 11,500 Cr total, ~INR 1,200 Cr spent, commissioning H2 FY28–FY29Timeline drift from Q4 FY28
Sep 2026Media reported management guidance of INR 8,000–8,500 Cr peak debtLeverage visibility
29 Sep 2026DCTL chlorination & specialty plant (~INR 300 Cr) commissioned at DahejAI portfolio broadening
1 Oct 2026Stock closed at INR 1,492.80 (−2.4% on the day), ~21% below 52-week highPost-results gains fully reversed
PendingQ2 FY27 results (quarter to 30 Sep 2026)Not yet released as of dossier date

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment: Advanced Intermediates revenue rose from INR 25,110 Mn in FY2022 to INR 25,530 Mn in FY2026.
Deepak Nitrite Limited — Revenue by Segment
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Advanced Intermediates revenue25,11030,34027,24025,27025,530
Phenolics revenue43,03049,71050,03058,05054,010
Inter-segment elimination-120-320-460-500-670
Consolidated revenue from operations68,02079,72076,82082,82078,870

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.